1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(3-thiazolidinyl)-3-quinolinecarboxylic acid | 93509-80-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(3-thiazolidinyl)-3-quinolinecarboxylic acid
• 英文别名: 1-ethyl-6-fluoro-4-oxo-7-(1,3-thiazolidin-3-yl)quinoline-3-carboxylic acid
• CAS: 93509-80-9
• 化学式: C₁₅H₁₅FN₂O₃S
• 分子量: 322.36
• InChiKey: UJCHIDHSGILYSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  86.2
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3,7,11,15-四甲基十六碳-2,6,10,14-四烯-1-醇 、 四氢噻唑 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 以11%的产率得到1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(3-thiazolidinyl)-3-quinolinecarboxylic acid
  参考文献：
  名称：

  Antibacterial thiazolidine or thiomorpholine substituted quinolines

  摘要：

  某些噻唑啉或硫代吗啡取代的喹啉和吡啶苯并噁唑化合物是抗菌剂。本发明揭示了它们的制备方法和用途。

  公开号：

  US04473568A1

文献信息

• Antibacterial thiazolidine or thiomorpholine substituted quinolines
  申请人：Warner Lambert Company

  公开号：US04473568A1

  公开（公告）日：1984-09-25

  Certain thiazolidine or thiomorpholine substituted quinoline and pyridobenzoxazine compounds are antibacterial agents. Method for their preparation and use are disclosed.

  某些噻唑啉或硫吗啉取代的喹啉和吡啶并苯并噁嗪化合物是抗菌剂。本发明揭示了它们的制备方法和使用方法。
• HUTT, M. P. ,, JR.
  作者：HUTT, M. P. ,, JR.

  DOI：——

  日期：——
• US4473568A
  申请人：——

  公开号：US4473568A

  公开（公告）日：1984-09-25
• New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay
  作者：John M. Domagala、Lori Doyle Hanna、Carl L. Heifetz、Marland P. Hutt、Thomas F. Mich、Joseph P. Sanchez、Marjorie Solomon

  DOI：10.1021/jm00153a015

  日期：1986.3

  A series of 60 newly synthesized and known quinolone antibacterials, including quinoline- and 1,8-naphthyridine-3-carboxylic acids, pyrido[2,3-d]pyrimidine-6-carboxylic acids, and some monocyclic 4-pyridone-3-carboxylic acids, were tested and compared in a newly established, easy to perform, DNA gyrase assay. The results were correlated with minimum inhibitory concentrations (MICs) against a variety of organisms. Among the known quinolones were 14 clinically significant drugs (oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, etc.) which were used as standards and compared side-by-side. The study focused on the changes in DNA gyrase inhibition brought about by certain features of the molecules, namely, the C6-fluorine or the nature of the C7 substituent. The intrinsic gyrase inhibition of the fused parent rings, quinoline vs. naphthyridine vs. pyrido[2,3-d]pyrimidine, was also explored. In all cases, loss of enzyme inhibition produced poor MICs, but some compounds with good DNA gyrase inhibition did not correspondingly inhibit bacterial growth. Possible explanations for this phenomena and the benefits of a DNA gyrase-MIC strategy for developing future structure-activity relationships are discussed.